Breaking Finance News

Zacks Investment Research downgraded XBiotech Inc (NASDAQ:XBIT) to Sell in a report released today.

Just yesterday XBiotech Inc (NASDAQ:XBIT) traded 0.66% lower at $15.11. The company’s 50-day moving average is $14.33 and its two hundred day average is $13.70. The last stock close is up 0.81% relative to the two hundred day moving average, compared to the Standard & Poor’s 500 Index which has fallen -0.01% over the same period. Volume of trade was was up over the average, with 586,522 shares of XBIT changing hands over the typical 419,355 shares..

Zacks Investment Research has downgraded XBiotech Inc(NASDAQ:XBIT) to Sell in a statement released Saturday August 20 2016.

Recent Performance Graph:

XBiotech Inc (NASDAQ:XBIT)

A total of 1 brokerage has released a report on the company. Zero rate the company a strong buy, one analyst rate the stock a buy, 0 firms rate the company a hold, 0 rate the stock to underperform, and lastly 0 analystsrate the company as sell with an average target of $24.00

XBiotech Inc has a 52 week low of $6.36 and a one-year high of $25.00. XBIT’s total market value is currently $0.0.

Brief Synopsis About XBiotech Inc (NASDAQ:XBIT)

XBiotech Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing True Human monoclonal antibodies for treating a range of diseases. The Company focuses on bringing its lead product candidate, Xilonix (MABp1), to market. The Company has also developed a True Human monoclonal antibody discovery platform and manufacturing system. The Company’s therapeutic antibody Xilonix is being evaluated as a monotherapy to treat advanced stages of colorectal cancer. Xilonix neutralizes a pro-inflammatory protein produced by leukocytes and other cells, interleukin-1 alpha (IL-1a). The Company completed a Phase I and II clinical trial for MABp1 as a treatment for cancer at MD Anderson Cancer Center. The Company is also investigating MABp1 in clinical trials for other indications, including vascular disease, type II diabetes, and acne and psoriasis.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *